Overall, the evidence for CDK4/6i continuation beyond progression is encouraging but mixed, underscoring the need for mechanistic studies of CDK4/6i-resistant proliferation to guide post-progression treatment strategies for HR+/HER2− breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.